PL374673A1 - Izolacja i identyfikacja komórek T - Google Patents
Izolacja i identyfikacja komórek TInfo
- Publication number
- PL374673A1 PL374673A1 PL03374673A PL37467303A PL374673A1 PL 374673 A1 PL374673 A1 PL 374673A1 PL 03374673 A PL03374673 A PL 03374673A PL 37467303 A PL37467303 A PL 37467303A PL 374673 A1 PL374673 A1 PL 374673A1
- Authority
- PL
- Poland
- Prior art keywords
- isolation
- cells
- identification
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4632—T-cell receptors [TCR]; antibody T-cell receptor constructs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46432—Nervous system antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rehabilitation Therapy (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40252102P | 2002-08-08 | 2002-08-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
PL374673A1 true PL374673A1 (pl) | 2005-10-31 |
PL214283B1 PL214283B1 (pl) | 2013-07-31 |
Family
ID=31715870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL374673A PL214283B1 (pl) | 2002-08-08 | 2003-08-06 | Sposób izolacji komórek T, sposób wytwarzania autologicznej szczepionki komórek T, autologiczna szczepionka komórek T, zastosowanie autologicznej szczepionki komórek T |
Country Status (19)
Country | Link |
---|---|
US (2) | US7695713B2 (pl) |
EP (2) | EP1546719B1 (pl) |
JP (2) | JP4705371B2 (pl) |
KR (1) | KR100795840B1 (pl) |
CN (1) | CN100567987C (pl) |
AU (1) | AU2003258090B2 (pl) |
BR (1) | BRPI0305769A8 (pl) |
CA (2) | CA2492848C (pl) |
ES (2) | ES2537951T3 (pl) |
HK (1) | HK1082520A1 (pl) |
IL (1) | IL166332A (pl) |
MX (1) | MXPA05001044A (pl) |
NO (2) | NO338881B1 (pl) |
NZ (1) | NZ537816A (pl) |
PL (1) | PL214283B1 (pl) |
PT (2) | PT2363710E (pl) |
RU (1) | RU2327487C2 (pl) |
WO (1) | WO2004015070A2 (pl) |
ZA (1) | ZA200500985B (pl) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
WO2004015070A2 (en) * | 2002-08-08 | 2004-02-19 | Baylor College Of Medicine | Isolation and identification of t cells |
JP2008520684A (ja) | 2004-11-17 | 2008-06-19 | アブジェニックス・インコーポレーテッド | Il−13に対する完全ヒトモノクローナル抗体 |
JP5276846B2 (ja) * | 2005-09-13 | 2013-08-28 | 国立大学法人三重大学 | T細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞 |
ATE514081T1 (de) * | 2006-03-02 | 2011-07-15 | Antitope Ltd | T-zellen-testverfahren |
ES2686593T3 (es) | 2006-05-31 | 2018-10-18 | The Regents Of The University Of California | Expresión de CD127 que correlaciona inversamente con FoxP3 y la función supresora de Treg CD4+ |
GB0707933D0 (en) * | 2007-04-24 | 2007-05-30 | Apitope Technology Bristol Ltd | Disease markers |
US20090062237A1 (en) * | 2007-06-15 | 2009-03-05 | Mayo Foundation For Medical Education And Research | Evaluating immune competence |
AU2009316371B2 (en) * | 2008-11-21 | 2014-02-20 | University Of Miami | HIV/SIV vaccines for the generation of mucosal and systemic immunity |
EP2449103B1 (en) | 2009-06-29 | 2016-08-03 | California Institute of Technology | Isolation of unknown rearranged t-cell receptors from single cells |
WO2011080349A1 (en) * | 2010-01-04 | 2011-07-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Detection method of anti-myelin autoreactive t-cells and diagnostic method of autoimmune disease |
EP2539470B1 (en) * | 2010-02-24 | 2017-02-22 | The Board of Trustees of The Leland Stanford Junior University | Methods for autoimmune disease diagnosis, prognosis, and treatment |
DE102011050550A1 (de) * | 2011-05-20 | 2012-11-22 | Wolfgang Göhde | Verfahren und Anordnung zur Quantifizierung von Untergruppen aus einer Mischpopulation von Zellen |
CA2840424C (en) | 2011-07-01 | 2022-02-01 | Beckman Coulter, Inc. | Regulatory t cells and methods of identifying, obtaining and using to treat immuno-based disorders |
US11782053B2 (en) * | 2011-09-28 | 2023-10-10 | iRepertoire, Inc. | Identification of antigen-specific adaptive immune responses using ARM-PCR and high-throughput sequencing |
FR2992427A1 (fr) * | 2012-06-20 | 2013-12-27 | Assist Publ Hopitaux De Paris | Methode de pronostic d'un lymphome et kit pour sa mise en oeuvre |
BR112014032677A2 (pt) * | 2012-06-27 | 2019-01-15 | Univ Rutgers | ensaios rápido para ativação de célula t por medições de rna usando citometria de fluxo |
GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
JP6508873B2 (ja) * | 2014-01-20 | 2019-05-08 | 国立大学法人富山大学 | 抗原特異的t細胞受容体の取得方法 |
EP3345000B1 (en) | 2015-08-31 | 2022-08-31 | Cedars-Sinai Medical Center | Novel blood cell biomarker for late onset alzheimer's disease |
EP3348632B1 (en) * | 2015-09-11 | 2021-11-03 | Astellas Pharma Inc. | Method for producing kidney progenitor cells |
BR112018072305A2 (pt) | 2016-05-25 | 2019-02-12 | The Council Of The Queensland Institute Of Medical Research | métodos de imunoterapia |
KR20190037243A (ko) * | 2016-06-28 | 2019-04-05 | 지니우스 바이오테크놀로지 인코포레이티드 | 면역치료를 위한 티 세포 조성물 |
CA3050299A1 (en) * | 2017-01-20 | 2018-07-26 | Atara Biotherapeutics, Inc. | Methods of treating multiple sclerosis using autologous t cells |
US20200408756A1 (en) * | 2017-06-14 | 2020-12-31 | Singapore Health Services Pte. Ltd. | Methods and kits for evaluating clinical outcomes of autoimmune disease |
WO2019133793A1 (en) | 2017-12-29 | 2019-07-04 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Compositions and methods for treating autoimmune disease |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5852225A (ja) * | 1981-09-22 | 1983-03-28 | Mitsui Pharmaceut Inc | 脱髄疾患治療剤 |
US5766920A (en) * | 1982-08-11 | 1998-06-16 | Cellcor, Inc. | Ex vivo activation of immune cells |
US4550086A (en) * | 1983-02-16 | 1985-10-29 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies that recognize human T cells |
IL69686A (en) * | 1983-09-11 | 1988-03-31 | Yeda Res & Dev | Compositions containing cell membrane proteins and process for their preparation |
US4608365A (en) * | 1984-03-30 | 1986-08-26 | University Of Southern California | Treatment of neurologic functions |
US4677061A (en) * | 1984-10-19 | 1987-06-30 | Genetic Systems Corporation | T-cell lymphocyte subset monitoring of immunologic disease |
US4902680A (en) | 1984-10-29 | 1990-02-20 | Chaovanee Aroonsakul | Treating central nervous system diseases |
US4898856A (en) * | 1984-10-29 | 1990-02-06 | Chaovanee Aroonsakul | Method for treating central nervous system diseases |
US4898857A (en) * | 1984-10-29 | 1990-02-06 | Chaovanee Aroonsakul | Treating control nervous system diseases |
US4897389A (en) * | 1984-10-29 | 1990-01-30 | Chaovanee Aroonsakul | Treating central nervous system diseases |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
CA1296622C (en) * | 1986-08-12 | 1992-03-03 | Jeffrey E. Anderson | Method and apparatus for automated assessment of the immunoregulatory status of the mononuclear leukocyte immune system |
US5849298A (en) * | 1987-06-24 | 1998-12-15 | Autoimmune Inc. | Treatment of multiple sclerosis by oral administration of bovine myelin |
US5039660A (en) * | 1988-03-02 | 1991-08-13 | Endocon, Inc. | Partially fused peptide pellet |
US4902857A (en) * | 1988-12-27 | 1990-02-20 | American Telephone And Telegraph Company, At&T Bell Laboratories | Polymer interconnect structure |
US5242687A (en) * | 1989-03-15 | 1993-09-07 | Tkb Associates Limited Partnership | Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells |
US5837246A (en) * | 1989-03-21 | 1998-11-17 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
US6221352B1 (en) * | 1989-03-21 | 2001-04-24 | The Immune Response Corporation | Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells |
US5861164A (en) * | 1989-03-21 | 1999-01-19 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
US6007815A (en) * | 1989-03-21 | 1999-12-28 | The Immune Response Corporation | Anti-idiotype vaccination against diseases resulting from pathogenic responses by specific T cell populations |
US5612035A (en) * | 1989-03-21 | 1997-03-18 | The Immune Response Corporation | Vaccination against diseases resulting from pathogenic responses by specific T cell populations |
US6207645B1 (en) * | 1989-03-21 | 2001-03-27 | The Immune Response Corporation | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations |
US5614192A (en) * | 1989-07-19 | 1997-03-25 | Connective Therapeutics, Inc. | T cell receptor peptides as therapeutics for immune-related disease |
US5776459A (en) * | 1989-07-19 | 1998-07-07 | Connetics Corporation | TCR V beta 5 peptides |
US5298396A (en) * | 1989-11-15 | 1994-03-29 | National Jewish Center For Immunology And Respiratory Medicine | Method for identifying T cells disease involved in autoimmune disease |
IL97709A (en) | 1990-03-30 | 2005-05-17 | Brigham & Womens Hospital | Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis |
AU8407091A (en) | 1990-07-06 | 1992-02-04 | Allergene, Inc. | Mouse/human heterohybrid cell line el41 and methods for the production of human monoclonal antibodies |
US5668117A (en) * | 1991-02-22 | 1997-09-16 | Shapiro; Howard K. | Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments |
US5211952A (en) * | 1991-04-12 | 1993-05-18 | University Of Southern California | Contraceptive methods and formulations for use therein |
US6083503A (en) * | 1991-08-28 | 2000-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection |
US5480895A (en) * | 1991-09-27 | 1996-01-02 | New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery | Method of producing antibodies to a restricted population of T lymphocytes, antibodies produced therefrom and methods of use thereof |
US5545716A (en) * | 1992-09-08 | 1996-08-13 | University Of Florida | Superantigen agonist and antagonist peptides |
EP0688223A4 (en) * | 1993-03-12 | 1998-05-13 | Cellcor Inc | TITRATION METHOD -i (IN VITRO) FOR MEASURING THE DEGREE OF ACTIVATION OF IMMUNE CELLS |
WO1994022451A1 (en) * | 1993-04-07 | 1994-10-13 | Oklahoma Medical Research Foundation | Selective regulation of b lymphocyte precursors by hormones |
AU6376194A (en) | 1993-05-14 | 1994-12-12 | Dr. L. Willems-Instituut | Human t cell monoclone, process for its production and its use, diagnostic of infectious diseases, autoimmune diseases, t-cell mediated allergies and cancer |
IL110787A0 (en) * | 1993-08-27 | 1994-11-11 | Sandoz Ag | Biodegradable polymer, its preparation and pharmaceutical composition containing it |
US5956058A (en) * | 1993-11-05 | 1999-09-21 | Seiko Epson Corporation | Ink jet print head with improved spacer made from silicon single-crystal substrate |
US5552300A (en) | 1994-01-13 | 1996-09-03 | T Cell Sciences, Inc. | T cell antigen receptor V region proteins and methods of preparation thereof |
US6410518B1 (en) * | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US5674487A (en) * | 1994-09-28 | 1997-10-07 | Univ Jefferson | Method for treating autoimmune diseases |
US6033661A (en) * | 1995-06-07 | 2000-03-07 | Thomas Jefferson University | Composition and method for allogenetic mononuclear cell immunotherapy |
US5723503A (en) | 1994-09-28 | 1998-03-03 | Thomas Jefferson University | Biological treatment for rheumatoid arthritis |
US6096314A (en) * | 1994-10-07 | 2000-08-01 | Yeda Research And Development Co. Ltd. | Peptides and pharmaceutical compositions comprising them |
WO1996016085A1 (en) * | 1994-11-18 | 1996-05-30 | Neurocrine Biosciences, Inc. | Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein |
FR2727117A1 (fr) * | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
US6218166B1 (en) * | 1994-12-09 | 2001-04-17 | John Wayne Cancer Institute | Adjuvant incorporation into antigen carrying cells: compositions and methods |
US5874531A (en) * | 1995-03-07 | 1999-02-23 | President And Fellows Of Harvard College | Identification of self and non-self antigens implicated autoimmune disease |
US5869057A (en) * | 1995-06-07 | 1999-02-09 | Rock; Edwin P. | Recombinant vaccines to break self-tolerance |
SE9502921D0 (sv) * | 1995-08-23 | 1995-08-23 | Astra Ab | New compounds |
US5739307A (en) * | 1995-08-28 | 1998-04-14 | Washington University | Polynucleotide encoding neurturin neurotrophic factor |
US5716946A (en) * | 1996-02-13 | 1998-02-10 | Wisconsin Alumni Research Foundation | Multiple sclerosis treatment |
AU5671196A (en) * | 1996-03-28 | 1997-10-17 | Immulogic Pharmaceutical Corporation | Myelin oligodendrocyte glycoprotein peptides and uses thereof |
US5750356A (en) * | 1996-05-31 | 1998-05-12 | Anergen, Inc. | Method for monitoring T cell reactivity |
US5849886A (en) * | 1996-07-10 | 1998-12-15 | Oy Aboatech Ab | Extraction of myelin basic protein |
US20010031253A1 (en) * | 1996-07-24 | 2001-10-18 | Gruenberg Micheal L. | Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease |
US6130087A (en) * | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
AU743855B2 (en) * | 1996-10-11 | 2002-02-07 | Regents Of The University Of California, The | Cancer immunotherapy using tumor cells combined with mixed lymphocytes |
US6054292A (en) * | 1997-07-18 | 2000-04-25 | Incyte Pharmaceuticals, Inc. | T-cell receptor protein |
US20020009448A1 (en) | 1997-09-19 | 2002-01-24 | Leslie P. Weiner | T-cell vaccination for the treatment of multiple sclerosis |
US20020072493A1 (en) * | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
US20020001841A1 (en) * | 1998-06-26 | 2002-01-03 | Keld Kaltoft | Continuous t-cell lines |
CA2335749A1 (en) * | 1998-06-26 | 2000-01-06 | B. Michael Longenecker | Method of detecting t-cell activation |
WO2000014116A1 (en) | 1998-09-04 | 2000-03-16 | Baylor College Of Medicine | T cell peptides as therapeutics for immune-related disease |
EP1159457B1 (en) * | 1999-02-23 | 2010-11-03 | Baylor College Of Medicine | T cell receptor vbeta - dbeta - jbeta) sequence and methods for its detection |
US6187750B1 (en) * | 1999-08-25 | 2001-02-13 | Everyoung Technologies, Inc. | Method of hormone treatment for patients with symptoms consistent with multiple sclerosis |
EP1224291A1 (en) * | 1999-10-28 | 2002-07-24 | Universite De Geneve | Multiple sclerosis-related superantigen |
US6746670B2 (en) * | 2000-08-15 | 2004-06-08 | Schering Corporation | Regulatory T cells; methods |
WO2002016434A1 (en) | 2000-08-22 | 2002-02-28 | Baylor College Of Medicine | T CELL RECEPTOR Vβ-Dβ-Jβ SEQUENCE AND METHODS FOR ITS DETECTION |
US7658926B2 (en) * | 2001-09-14 | 2010-02-09 | Opexa Pharmaceuticals, Inc. | Autologous T-cell vaccines materials and methods |
WO2003042377A1 (en) * | 2001-11-07 | 2003-05-22 | Kirin Beer Kabushiki Kaisha | Expansion of t cells in vitro and expanded t cell populations |
US20050181459A1 (en) * | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
WO2004015070A2 (en) * | 2002-08-08 | 2004-02-19 | Baylor College Of Medicine | Isolation and identification of t cells |
-
2003
- 2003-08-06 WO PCT/US2003/024548 patent/WO2004015070A2/en active Application Filing
- 2003-08-06 ES ES03784936.1T patent/ES2537951T3/es not_active Expired - Lifetime
- 2003-08-06 MX MXPA05001044A patent/MXPA05001044A/es active IP Right Grant
- 2003-08-06 JP JP2004527772A patent/JP4705371B2/ja not_active Expired - Fee Related
- 2003-08-06 BR BRPI0305769A patent/BRPI0305769A8/pt not_active IP Right Cessation
- 2003-08-06 EP EP03784936.1A patent/EP1546719B1/en not_active Expired - Lifetime
- 2003-08-06 NZ NZ537816A patent/NZ537816A/en not_active IP Right Cessation
- 2003-08-06 CA CA2492848A patent/CA2492848C/en not_active Expired - Fee Related
- 2003-08-06 CN CNB038192349A patent/CN100567987C/zh not_active Expired - Fee Related
- 2003-08-06 PT PT101822963T patent/PT2363710E/pt unknown
- 2003-08-06 RU RU2005106842/15A patent/RU2327487C2/ru not_active IP Right Cessation
- 2003-08-06 ES ES10182296.3T patent/ES2545736T3/es not_active Expired - Lifetime
- 2003-08-06 AU AU2003258090A patent/AU2003258090B2/en not_active Ceased
- 2003-08-06 PL PL374673A patent/PL214283B1/pl unknown
- 2003-08-06 KR KR1020057001587A patent/KR100795840B1/ko not_active IP Right Cessation
- 2003-08-06 PT PT37849361T patent/PT1546719E/pt unknown
- 2003-08-06 CA CA2759572A patent/CA2759572A1/en not_active Abandoned
- 2003-08-06 US US10/524,300 patent/US7695713B2/en not_active Expired - Fee Related
- 2003-08-06 EP EP10182296.3A patent/EP2363710B1/en not_active Expired - Lifetime
-
2005
- 2005-01-17 IL IL166332A patent/IL166332A/en not_active IP Right Cessation
- 2005-01-26 NO NO20050447A patent/NO338881B1/no not_active IP Right Cessation
- 2005-02-02 ZA ZA200500985A patent/ZA200500985B/xx unknown
-
2006
- 2006-03-16 HK HK06103358.4A patent/HK1082520A1/xx not_active IP Right Cessation
-
2010
- 2010-02-23 US US12/711,160 patent/US20100239548A1/en not_active Abandoned
- 2010-04-21 JP JP2010098263A patent/JP2010178759A/ja active Pending
-
2015
- 2015-04-16 NO NO20150482A patent/NO20150482L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL166332A0 (en) | Isolation and identification of t cells | |
EP1434887A4 (en) | METHOD OF ISOLATING CELLS AND USE THEREOF | |
AU2003273542A8 (en) | Methods of identifying and isolating stem cells and cancer stem cells | |
AU2003239159A8 (en) | Placental derived stem cells and uses thereof | |
AU2003217337A8 (en) | High-throughput cell identification and isolation method and apparatus | |
EP1689854A4 (en) | PLACENTAR STEM CELLS AND USES THEREOF | |
AU2002950762A0 (en) | Identification and selection of mechanical keys | |
PL375691A1 (pl) | Imidazolopirydyny i sposoby ich wytwarzania i stosowania | |
EP1403942A4 (en) | CELL AND CELL PACK | |
AU2003288902A8 (en) | Microcapsules and methods of use | |
EP1474445A4 (en) | ADIPONECTIN GLYCO-ISOFORMS, AND USES THEREOF | |
IL166370A0 (en) | Embryonic stem cell markers and uses thereof | |
AU2003294246A8 (en) | Circulating stem cells and uses related thereto | |
PL375355A1 (pl) | Nowe lipazy i ich zastosowanie | |
EP1476150A4 (en) | CARBOXY FULLERES AND USE METHOD THEREFOR | |
EP1687411A4 (en) | IDENTIFICATION AND ISOLATION OF HEMATOPOIETIC STEM CELLS | |
HK1131514A1 (en) | Method of isolation and purification | |
EP1581637A4 (en) | MATERIALS AND METHODS WITH HUMAN STEM CELLS | |
AU2003235577A8 (en) | Identification of small ruminants | |
AU2003299914A8 (en) | Isolation and identification of cross-reactive t cells | |
EP1697715A4 (en) | IDENTIFICATION, INSULATION AND ELIMINATION OF CANCER STEM CELLS | |
AU2003285686A8 (en) | Glycoisoforms of adiponectin and uses thereof | |
AU2002352696A8 (en) | Cell substrates and methods of use thereof | |
AU2003217743A8 (en) | Magnetic immobilization of cells | |
HK1097875A1 (en) | Adenovirus-transfected primary cells and methods of pathway mapping |